Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Retrospective study on the efficacy of baricitinib in 12 COVID-19 patients with moderate pneumonia.
Description: All adverse event recording
Measure: To assess the safety of baricitinib combined with antiviral (lopinavir-ritonavir) in terms of serious or non-serious adverse events incidence rate. Time: 2 weeksDescription: The percentage of patients improving the clinical and respiratory parameters compared with controls.
Measure: To evaluate the impact of baricitinib in terms of clinical, laboratory, respiratory parameters. Time: 2 weeksDescription: The percentage of ICU admission in baricitinib group as compared with controls.
Measure: ICU admission rate Time: 2 weeksDescription: The percentage of discharged in baricitinib group as compared with controls.
Measure: Discharge rate. Time: 2 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports